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Background 
In November 2001, the Food and Drug Administration (FDA) 
approved drotrecogin alfa (activated) (DrotAA) for adults 
who had severe sepsis and a high risk of death. The FDA 
required a study to evaluate the efficacy of DrotAA for adults 
who had severe sepsis and a low risk of death. 
Methods 
Design and setting: Double-blind, randomized, placebo-
controlled trial conducted in 516 centers in 34 countries. 
Subjects: Adult patients with severe sepsis and a low risk 
of death (defined by an Acute Physiology and Chronic 
Health Evaluation [APACHE II] score <25 or single-organ 
failure). 
Intervention:  Subjects were randomized to receive an 
intravenous infusion of placebo or DrotAA (24 µg per 
kilogram of body weight per hour) for 96 hours. 
Measurements: The prospectively defined primary end 
point was death from any cause and was assessed 28 days 
after the start of the infusion. In-hospital mortality within 90 
days after the start of the infusion was measured, and 
safety information was collected. 
Results:  Enrollment in the trial was terminated early 
because of a low likelihood of meeting the prospectively 
defined objective of demonstrating a significant reduction in 
the 28-day mortality rate with the use of DrotAA. The study 
enrolled 2640 patients and collected data on 2613 (1297 in 
the placebo group and 1316 in the DrotAA group) at the 28-
day follow-up. There were no statistically significant 
differences between the placebo group and the DrotAA 
group in 28-day mortality (17.0 percent in the placebo group 
vs. 18.5 percent in the DrotAA group; P=0.34; relative risk, 
1.08; 95 percent confidence interval, 0.92 to 1.28) or in in-
hospital mortality (20.5 percent vs. 20.6 percent; P=0.98; 
relative risk, 1.00; 95 percent confidence interval, 0.86 to 
1.16). The rate of serious bleeding was greater in the 
DrotAA group than in the placebo group during both the 
infusion (2.4 percent vs. 1.2 percent, P=0.02) and the 28-
day study period (3.9 percent vs. 2.2 percent, P=0.01). 
Conclusion 
The absence of a beneficial treatment effect, coupled with 
an increased incidence of serious bleeding complications, 
indicates that DrotAA should not be used in patients with 
severe sepsis who are at low risk for death, such as those 
with single-organ failure or an APACHE II score less than 
25. 
Commentary 
Severe sepsis is a syndrome defined as acute organ 
dysfunction secondary to infection and characterized by 
dysregulation of inflammation, coagulation, and other acute 
phase responses. Hospital morality for patients with severe 
sepsis is approximately 30%, rising to as high as 50% in the 
presence of septic shock. Activated protein C, or 
drotrecogin alfa (activated) (DrotAA), inhibits coagulation 
factors Va and VIIIa, reducing coagulopathy in patients with 
severe sepsis [2]. In the Recombinant Human Activated 
Protein C Worldwide Evaluation in Severe Sepsis 
(PROWESS) trial, DrotAA resulted in a 6.1% absolute 
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reduction in 28-day mortality in adults with severe sepsis as 
compared to placebo. The greatest benefit was seen in 
patients at high risk of death. Based on these results, in 
2001 the United States and European drug regulatory 
agencies approved DrotAA for use in adult patients with 
severe sepsis and high risk of death, as defined by an 
Acute Physiology and Chronic Health Evaluation (APACHE 
II) score ≥ 25 or multiorgan failure. As a condition for 
approval, the manufacturer, Eli Lilly and Company, agreed 
to complete a number of phase IV studies evaluating the 
use of DrotAA in lower-risk patients with severe sepsis, in 
children with severe sepsis, and in patients receiving low-
dose heparin [3].  
In the Administration of Drotrecogin Alfa (Activated) in Early 
Stage Severe Sepsis (ADDRESS) study [1], Abraham and 
colleagues assessed the role of DrotAA in patients with 
severe sepsis and low risk of death. Subjects had a known 
or suspected infection and an APACHE II score of less than 
25 or single organ system failure. The protocol also 
permitted the enrollment of patients who were thought by 
the investigator to have a low risk of death despite a higher 
APACHE II score or multiorgan failure. Initially designed to 
include 11,444 patients, the trial was stopped early because 
of futility after 2,640 subjects were enrolled.  
Data from 2,613 patients were available for analysis. 
Control and experimental groups were evenly matched in 
terms of their baseline characteristics, disease severity, type 
of organ dysfunction, and source of infection. There were no 
statistically significant differences in 28-day or hospital 
mortality between groups, but rates of serious bleeding 
were greater in the DrotAA group both during the infusion 
(2.4% vs. 1.2%, P=0.02) and in the 28-day study period 
(3.9% vs. 2.2%, P=0.01) and were similar to rates seen in 
the PROWESS trial.  
There has been considerable discussion in the literature 
about the subgroup of subjects at high-risk of death, who 
were included in ADDRESS at the discretion of the 
investigators [4-6]. Among the 324 (12.3%) subjects with 
APACHE II scores of 25 or more, there was no observed 
benefit for DrotAA use. In fact, 28-day mortality was higher 
in DrotAA-treated subjects (29.5% vs. 24.7%), although this 
difference was not statistically significant. While this finding 
would seem to contradict the results of PROWESS, there 
were important imbalances in baseline characteristics 
between the DrotAA and control groups in the high-risk 
subset of ADDRESS subjects. Specifically, DrotAA treated 
subjects were older and more likely to have multiorgan 
dysfunction and respiratory failure, making any conclusions 
about DrotAA’s effectiveness in high-risk patients limited at 
best. 
In 2003, critical care and infectious disease experts 
representing 11 international organizations developed 
management guidelines for severe sepsis and septic shock, 
under the auspices of the Surviving Sepsis Campaign [7]. 
Though DrotAA is an important drug with well-documented 
beneficial effects in patients with severe sepsis and high risk 
of death, it is just one of the recommended components for 
the management of septic patients (table). As with many 
disease states, time is of the essence in severe sepsis. 
Early goal-directed therapy has been shown to improve 
outcome in severe sepsis [8]. Furthermore, two studies 
have shown that time to treatment with DrotAA has an 
influence on mortality [9,10], with the maximum beneficial 
effect being observed if treatment is started within 24 hours 
of the onset of sepsis-induced organ dysfunction. 
Recognizing this, some hospitals are establishing teams of 
emergency department and intensive care unit specialists to 
facilitate rapid sepsis identification, assessment, and 
treatment. 
Table: Select components of the Surviving Sepsis 
Campaign [7] 
  Early goal-directed resuscitation  
  Appropriate diagnostic studies prior to antibiotics 
  Early broad-spectrum antibiotics 
  Narrowing antibiotic therapy based on microbiology 
and clinical data 
  Source control 
  Stress-dose steroids for septic shock 
  DrotAA for patients with severe sepsis and high risk 
for death 
  Target hemoglobin values of 7–9 g/dL in absence of 
coronary artery disease or acute hemorrhage 
  Lung protective ventilation for ALI/ARDS 
  Semirecumbent bed position 
  Protocols for weaning and sedation/analgesia 
  Avoidance of neuromuscular blockers 
  Maintenance of blood glucose <150 mg/dL 
  Deep vein thrombosis/stress ulcer prophylaxis 
ALI/ARDS = Acute lung injury/acute respiratory distress 
syndrome 
Recommendation 
We concur with the ADDRESS authors. DrotAA should not 
be used in patients with severe sepsis and low risk for 
death. 
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